{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:08:32Z","timestamp":1783490912100,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Zhongshan social welfare science and technology research project","award":["2021B1102"],"award-info":[{"award-number":["2021B1102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91337-w","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T15:57:55Z","timestamp":1740585475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis the diagnostic performance of H4C6\/SOX1-OT gene methylation in bladder cancer based on urine sample"],"prefix":"10.1038","volume":"15","author":[{"given":"Wan-Dang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Ran","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Mao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Mei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"91337_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"91337_CR2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.eururo.2018.09.001","volume":"74","author":"M Cumberbatch","year":"2018","unstructured":"Cumberbatch, M. et al. Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018. Eur. Urol. 74, 784\u2013795 (2018).","journal-title":"Eur. Urol."},{"key":"91337_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.7326\/M15-1496","volume":"164","author":"M Nielsen","year":"2016","unstructured":"Nielsen, M., Qaseem, A. & High Value Care Task Force of the American College of Physicians &. Hematuria as a marker of occult urinary tract cancer: advice for High-Value care from the American college of physicians. Ann. Intern. Med. 164, 488\u2013497 (2016).","journal-title":"Ann. Intern. Med."},{"key":"91337_CR4","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat, E. et al. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet 400, 1712\u20131721 (2022).","journal-title":"Lancet"},{"key":"91337_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0022-5347(06)00576-3","volume":"176","author":"MF Sarosdy","year":"2006","unstructured":"Sarosdy, M. F. et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J. Urol. 176, 44\u201347 (2006).","journal-title":"J. Urol."},{"key":"91337_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.juro.2007.03.034","volume":"178","author":"HB Grossman","year":"2007","unstructured":"Grossman, H. B. et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J. Urol. 178, 62\u201367 (2007).","journal-title":"J. Urol."},{"key":"91337_CR7","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.juro.2007.03.028","volume":"178","author":"Y Fradet","year":"2007","unstructured":"Fradet, Y. et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J. Urol. 178, 68\u201373 (2007). discussion 73.","journal-title":"J. Urol."},{"key":"91337_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk, M. et al. European association of urology guidelines on Non-muscle-invasive bladder Cancer (Ta, T1, and carcinoma in Situ). Eur. Urol. 81, 75\u201394 (2022).","journal-title":"Eur. Urol."},{"key":"91337_CR9","doi-asserted-by":"publisher","first-page":"66e25","DOI":"10.1016\/j.urolonc.2014.06.008","volume":"33","author":"FA Yafi","year":"2015","unstructured":"Yafi, F. A. et al. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol. Oncol. 33, 66e25\u201366e31 (2015).","journal-title":"Urol. Oncol."},{"key":"91337_CR10","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","volume":"64","author":"M Burger","year":"2013","unstructured":"Burger, M. et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on Raw data. Eur. Urol. 64, 846\u2013854 (2013).","journal-title":"Eur. Urol."},{"key":"91337_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk, M. et al. European association of urology guidelines on Non-muscle-invasive bladder Cancer (TaT1 and carcinoma in Situ) \u2013\u20092019 update. Eur. Urol. 76, 639\u2013657 (2019).","journal-title":"Eur. Urol."},{"key":"91337_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cncy.21327","volume":"121","author":"H Dimashkieh","year":"2013","unstructured":"Dimashkieh, H. et al. Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation. Cancer Cytopathol. 121, 591\u2013597 (2013).","journal-title":"Cancer Cytopathol."},{"key":"91337_CR13","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.3892\/ol.2017.5926","volume":"13","author":"T Lin","year":"2017","unstructured":"Lin, T. et al. Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma. Oncol. Lett. 13, 3928\u20133934 (2017).","journal-title":"Oncol. Lett."},{"key":"91337_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.5489\/cuaj.600","volume":"2","author":"LI Budman","year":"2008","unstructured":"Budman, L. I., Kassouf, W. & Steinberg, J. R. Biomarkers for detection and surveillance of bladder cancer. Can. Urol. Assoc. J. 2, 212\u2013221 (2008).","journal-title":"Can. Urol. Assoc. J."},{"key":"91337_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2490-12-23","volume":"12","author":"M Miyake","year":"2012","unstructured":"Miyake, M. et al. Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urol. 12, 23 (2012).","journal-title":"BMC Urol."},{"key":"91337_CR16","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.1096\/fj.201903176R","volume":"34","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. Loss of GATA6 expression promotes lymphatic metastasis in bladder cancer. FASEB J. 34, 5754\u20135766 (2020).","journal-title":"FASEB J."},{"key":"91337_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1146\/annurev-pathol-042220-022304","volume":"17","author":"A Papanicolau-Sengos","year":"2022","unstructured":"Papanicolau-Sengos, A. & Aldape, K. D. N. A. Methylation profiling: an emerging paradigm for Cancer diagnosis. Annu. Rev. Pathol. 17, 295\u2013321 (2022).","journal-title":"Annu. Rev. Pathol."},{"key":"91337_CR18","unstructured":"Silva-Ferreira, M. et al. Diagnostic test accuracy of urinary DNA Methylation-based biomarkers for the detection of primary and recurrent bladder cancer: A systematic review and Meta-analysis. Eur. Urol. Focus S2405\u20134569(24)00088\u201300089 [pii] (2024)."},{"key":"91337_CR19","doi-asserted-by":"publisher","first-page":"147352","DOI":"10.1016\/j.gene.2023.147352","volume":"866","author":"N Varol","year":"2023","unstructured":"Varol, N. et al. Methylation analysis of histone 4-related gene HIST1H4F and its effect on gene expression in bladder cancer. Gene 866, 147352 (2023).","journal-title":"Gene"},{"key":"91337_CR20","doi-asserted-by":"publisher","first-page":"6278","DOI":"10.1172\/JCI139597","volume":"130","author":"X Chen","year":"2020","unstructured":"Chen, X. et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer. J. Clin. Invest. 130, 6278\u20136289 (2020).","journal-title":"J. Clin. Invest."},{"key":"91337_CR21","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.eururo.2016.06.035","volume":"70","author":"CM Dahmcke","year":"2016","unstructured":"Dahmcke, C. M. et al. A prospective blinded evaluation of Urine-DNA testing for detection of urothelial bladder carcinoma in patients with gross hematuria. Eur. Urol. 70, 916\u2013919 (2016).","journal-title":"Eur. Urol."},{"key":"91337_CR22","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.juro.2016.09.118","volume":"197","author":"KE van Kessel","year":"2017","unstructured":"van Kessel, K. E. et al. Validation of a DNA Methylation-Mutation urine assay to select patients with hematuria for cystoscopy. J. Urol. 197, 590\u2013595 (2017).","journal-title":"J. Urol."},{"key":"91337_CR23","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.euf.2018.09.016","volume":"HOXA9","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. PCDH17, POU4F2, and ONECUT2 as a urinary biomarker combination for the detection of bladder Cancer in Chinese patients with hematuria. Eur. Urol. Focus 6. HOXA9, 284\u2013291 (2020).","journal-title":"Eur. Urol. Focus 6"},{"key":"91337_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13148-021-01073-x","volume":"13","author":"W Ruan","year":"2021","unstructured":"Ruan, W. et al. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer. Clin. Epigenetics. 13, 91 (2021).","journal-title":"Clin. Epigenetics"},{"key":"91337_CR25","doi-asserted-by":"publisher","first-page":"342e15","DOI":"10.1016\/j.urolonc.2018.04.001","volume":"36","author":"RQ Guo","year":"2018","unstructured":"Guo, R. Q. et al. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study. Urol. Oncol. 36, 342e15\u2013342e23 (2018).","journal-title":"Urol. Oncol."},{"key":"91337_CR26","doi-asserted-by":"publisher","first-page":"597486","DOI":"10.3389\/fonc.2020.597486","volume":"10","author":"Y Xu","year":"2020","unstructured":"Xu, Y. et al. A Urine-Based liquid biopsy method for detection of upper tract urinary carcinoma. Front. Oncol. 10, 597486 (2020).","journal-title":"Front. Oncol."},{"key":"91337_CR27","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jmoldx.2023.05.003","volume":"25","author":"TJ Oh","year":"2023","unstructured":"Oh, T. J. et al. Evaluation of sensitive urine DNA-Based PENK methylation test for detecting bladder Cancer in patients with hematuria. J. Mol. Diagn. 25, 646\u2013654 (2023).","journal-title":"J. Mol. Diagn."},{"key":"91337_CR28","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.2147\/CMAR.S300861","volume":"13","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. SDC2 and TFPI2 methylation in stool samples as an integrated biomarker for early detection of colorectal Cancer. Cancer Manag Res. 13, 3601\u20133617 (2021).","journal-title":"Cancer Manag Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91337-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91337-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91337-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T15:58:01Z","timestamp":1740585481000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91337-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91337"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91337-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Xiaolan Hospital of Zhongshan, the institutional review board number is ZSXL-LL2021-024. The methods were carried out in accordance with the approved guidelines. All the patients have been informed and signed informed consent before the experiments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"6961"}}